Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 2 | 4 | 1 | — | 1 | 7 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 2 | 1 | — | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 7 | — | — | — | 8 |
Neoplasms | D009369 | — | C80 | — | 3 | — | — | — | 3 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 1 | — | — | — | 2 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 1 | — | — | — | 2 |
Triple negative breast neoplasms | D064726 | — | — | — | 1 | — | — | — | 1 |
Hemangiosarcoma | D006394 | — | — | — | 1 | — | — | — | 1 |
Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Small cell lung carcinoma | D055752 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Patritumab deruxtecan |
INN | patritumab deruxtecan |
Description | Patritumab deruxtecan (MK-1022) is an experimental antibody–drug conjugate developed by Merck and Daiichi Sankyo to treat non-small-cell lung cancer.
|
Classification | Antibody |
Drug class | monoclonal antibodies; antineoplastics (camptothecin derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4594611 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 3XPI7EG4W8 (ChemIDplus, GSRS) |